Skip to main content
    I

    Imunon Inc (IMNN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.06
    +0.02 (+1.92%)

    Market Cap: $5.84M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(21/39)
    Avg Surprise
    -65.60%
    Streak
    10 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.55
    Range$-0.71 - $-0.45
    4 analysts
    EPS Revisions
    4
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.60+9.1%
    60d ago$-0.70+21.7%
    30d ago$-0.550.0%
    7d ago$-0.550.0%
    Current$-0.55
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.04
    Range$-0.51 - $0.64
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.04---
    Sep 26EST
    		-$-0.55---
    Jun 26
    Reported Aug 11
    		$-0.54$-0.94+42.55%Beat+71.1%
    Mar 26
    Reported May 12
    		$-0.84$-1.28+34.38%Beat+77.0%
    Dec 25
    Reported Mar 31
    		$-1.30$-1.82+28.57%Beat-420.0%
    Sep 25
    Reported Nov 13
    		$-1.16$-1.82+36.26%Beat+73.8%
    Jun 25
    Reported Aug 5
    		$-1.87N/A+56.91%Beat+71.9%
    Mar 25
    Reported May 12
    		$-3.65$-4.66+21.67%Beat+46.2%
    Dec 24
    Reported Feb 27
    		$-0.25$-0.36+30.56%Beat+51.9%
    Sep 24
    Reported Nov 7
    		$-4.43$-5.35+17.20%Beat+8.3%
    Jun 24
    Reported Aug 14
    		$-6.65$-6.65+0.00%Beat+10.9%
    Mar 24
    Reported May 13
    		$-6.78$-7.39+8.25%Beat+23.6%
    Dec 23
    Reported Mar 28
    		$-0.52$-0.41-26.83%Miss+67.7%
    Sep 23
    Reported Nov 14
    		$-4.83$-7.30+33.84%Beat+57.4%
    Jun 23
    Reported Aug 10
    		$-7.46$-7.70+3.12%Beat+34.3%
    Mar 23
    Reported May 11
    		$-8.87$-8.09-9.64%Miss+62.6%
    Dec 22
    Reported Mar 30
    		$-1.61$-0.85-89.41%Miss+55.5%
    Sep 22
    Reported Nov 14
    		$-11.35$-10.30-10.19%Miss+3.3%
    Jun 22
    Reported Aug 15
    		$-11.35$-11.80+3.81%Beat-1161.1%
    Mar 22
    Reported May 16
    		$-23.74$-13.30-78.50%Miss-1658.5%
    Dec 21
    Reported Mar 31
    		$-3.62$-0.90-302.22%Miss+63.0%
    Sep 21
    Reported Nov 15
    		$-11.74$-16.63+29.40%Beat+75.0%
    Jun 21
    Reported Aug 12
    		$-0.90$-1.20+25.00%Beat+97.4%
    Mar 21
    Reported May 14
    		$-1.35$-0.06-2150.00%Miss+55.0%
    Dec 20
    Reported Mar 19
    		$-9.78N/A+61.54%Beat+50.0%
    Sep 20
    Reported Nov 16
    		$-46.96$-25.43-84.66%Miss+4.0%
    Jun 20
    Reported Aug 14
    		$-35.22$-29.35-20.00%Miss+37.9%
    Mar 20
    Reported May 15
    		$-3.00$-2.55-17.65%Miss+87.2%
    Dec 19
    Reported Mar 25
    		$-19.57$-39.13+49.99%Beat-366.0%
    Sep 19
    Reported Nov 14
    		$-48.91$-52.83+7.42%Beat+3.9%
    Jun 19
    Reported Aug 14
    		$-56.74$-64.57+12.13%Beat+37.0%
    Mar 19
    Reported May 15
    		$-23.48N/A+51.99%Beat+52.0%
    Dec 18
    Reported Mar 29
    		$-4.20$-2.05-104.88%Miss+10.3%
    Sep 18
    Reported Nov 14
    		$-50.87$-43.04-18.19%Miss+62.9%
    Jun 18
    Reported Aug 14
    		$-90.00$-52.83-70.36%Miss+41.8%
    Mar 18
    Reported May 11
    		$-48.91$-58.70+16.68%Beat+85.1%
    Dec 17
    Reported Mar 27
    		$-4.68$-4.57-2.41%Miss+88.3%
    Sep 17
    Reported Nov 14
    		$-136.96$-109.57-25.00%Miss-
    Jun 17
    Reported Aug 14
    		$-154.57$-74.35-107.90%Miss-
    Mar 17
    Reported May 12
    		$-328.70$-301.31-9.09%Miss-
    Dec 16
    Reported Mar 16
    		$-39.90$-38.85-2.70%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.28EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-429.70%ROIC-104.27%
    Financial Health
    Debt/Equity1.68xInterest CoverageN/A
    Current Ratio1.82xQuick Ratio1.82x
    Trading Statistics
    Beta2.00Avg Volume118.52K
    52-Week High$5.2552-Week Low$0.96

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.12
    SMA 20$1.25
    SMA 50$1.44
    SMA 200$2.39
    EMA 10$1.12
    EMA 20$1.22
    EMA 50$1.41
    EMA 200$2.67

    MACD

    Line: -0.12Signal: -0.11Hist: -0.01

    ADX

    ADX: 27.5+DI: 9.6-DI: 22.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down84.0
    PSAR$1.08

    Bollinger Bands

    Upper Band$1.56
    Lower Band$0.94
    %B Position4990%(Upper)
    Band Width0.19

    RSI (14-Day)

    Oversold
    28.2

    Momentum Oscillators

    Stoch %K19.9
    Stoch %D19.6
    Williams %R-79.2
    ROC (10d)-19.7%
    Momentum-0.26
    CCI (20d)-98.2
    MFI (14d)15.7

    Volatility Measures

    ATR (14d)$0.10(9.7%)
    StdDev (20d)0.16
    Hist Vol65.3%(High)

    Volume Flow

    VWAP$1.05
    OBV559.8M
    AD Line55.5B
    CMF (20d)-0.136

    Volume Metrics

    Avg Vol (20d)121.2K
    Vol Ratio0.3x(Low)
    VWMA (20d)$1.30

    Pivot Points

    R3$1.12
    R2$1.10
    R1$1.07
    Pivot Point$1.05
    S1$1.02
    S2$1.00
    S3$0.97

    Advanced Oscillators

    TSI-41.22
    Ultimate Osc48.6
    KST-238.03

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$-725,202$0$0$0$727,160$0$0$0$7.05M$0
    Cost of Revenue$0$0$169,265$0$0$0$165,286$0$0$0$140,556$0
    Gross Profit$0$0$-169,265$0$0$0$-165,286$0$0$0$6.91M$0
    Operating Expenses$2.79M$4.31M$4.26M$3.48M$2.77M$4.15M$4.15M$4.96M$5.01M$5.01M$5.97M$3.90M
    R&D$1.46M$2.34M$2.49M$1.90M$1.23M$2.17M$2.23M$3.29M$2.82M$3.29M$3.55M$1.98M
    SG&A$1.33M$1.97M$1.77M$1.58M$1.54M$1.98M$1.91M$1.67M$2.19M$1.72M$2.41M$1.92M
    Operating Income$-2,791,546$-4,306,552$-4,261,703$-3,475,828$-2,767,864$-4,145,299$-4,146,182$-4,961,467$-5,013,351$-5,011,446$-5,967,627$-3,904,068
    Interest Income$32,518$57,530$38,853$46,704$27,305$42,804$88,957$115,992$225,334$81,921$195,428$427,454
    Interest Expense$77,273$0$0$0$0$0$0$0$0$0$-159,985$0
    Income Before Tax$-2,814,114$-4,249,022$-4,222,850$-3,429,124$-2,740,559$-4,102,495$-4,057,225$-4,845,475$-4,788,017$-4,929,525$-6,205,613$-3,476,614
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,814,114$-4,249,022$-4,222,850$-3,429,124$-2,740,559$-4,102,495$-4,057,225$-4,845,475$-4,788,017$-4,929,525$-4,888,133$-3,476,614
    EBITDA$-2,557,968$-4,140,008$-4,092,438$-3,308,794$-2,603,190$-3,947,372$-3,980,896$-4,772,217$-4,828,081$-4,833,136$-5,827,071$-3,650,654
    EBIT$-2,769,359$-4,306,552$-4,261,703$-3,475,828$-2,767,864$-4,145,299$-4,146,182$-4,961,467$-5,013,351$-5,011,446$-5,967,627$-3,904,068
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMNN

    News

    CBO0.SG Interactive Stock Chart | Imunon Inc. Stock - Yahoo Finance

    This page provides an interactive stock chart for Imunon Inc. (CBO0.SG) on Yahoo Finance, showing its current trading price and daily change. It includes options for different chart ranges and intervals...

    Yahoo! Finance Canada•10/14/26•Neutral

    Form 4 Imunon Inc: Stacy Lindborg (Director, President and CEO) For: 9 October

    This article reports on a Form 4 filing for Imunon Inc, detailing that Stacy Lindborg, who serves as Director, President, and CEO...

    Investing.com Nigeria•10/14/26•Neutral

    Form 4 Imunon Inc: Stacy Lindborg (Director, President and CEO) For: 9 October

    This article reports on a Form 4 filing for Imunon Inc, indicating that Stacy Lindborg, who serves as Director, President, and CEO...

    Investing.com India•10/14/26•Neutral

    Imunon CMO Douglas Faller Acquires 1,249 Shares at $1.08 Each on October 9, 2026

    Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc. (NASDAQ:IMNN), acquired 1,249 common stock shares on October 9, 2026. This acquisition, valued at $1.08 per share...

    Kalkine Media•10/14/26•Somewhat-Bullish

    Stock replaces cash salary as Imunon (IMNN) chairman acquires 7,800 shares at $1.08 each.

    Imunon, Inc.'s Executive Chairman of Board, Michael H. Tardugno, acquired 7,800 shares of common stock on October 9, 2026, as stock granted in lieu of cash for his base salary. The shares were valued at $1.08 each...

    Stock Titan•10/13/26•Neutral

    IMNN Valuation and Fair Value

    P/E
    -0.3x
    Forward P/E
    16.8x
    PEG
    5.0x
    P/B
    1.3x
    See GNG's fair value

    IMNN Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -104.3%
    ROE
    -429.7%

    IMNN Competitors

    CompanyTicker
    Can Fite Biopharma Ltd ADRCANF
    Sonoma Pharmaceuticals IncSNOA
    EvogeneEVGN
    enVVeno Medical CorpNVNO
    Lexaria Bioscience CorpLEXX
    Longeveron LLCLGVN
    Creative Medical Technology Holdings IncCELZ
    Scienture Holdings, Inc.SCNX

    Sector: Healthcare

    IMNN Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    1
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    IMNN Bull Case vs Bear Case

    Bull case

    • IMNN beat EPS estimates in 100.0% of its last 8 reported quarters.

    IMNN Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    33.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.55
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About IMNN

    Does IMNN pay dividends?

    Imunon Inc (IMNN) does not currently pay a regular dividend.

    What is IMNN's market cap?

    Imunon Inc (IMNN) has a market capitalization of $5.84M with a current stock price of $1.06.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In